Vanguard Capital Management
KYTX icon

Vanguard Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Vanguard Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
1,897,451
+114,109
+6% +$1.01M ﹤0.01% 2538
2026
Q1 		$15.4M Buy
+1,783,342
New +$14.9M ﹤0.01% 2493

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's KYTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Kyverna Therapeutics (KYTX) stake by 6.4% in Q2 2026, buying an estimated $1.01M and bringing the position to 1,897,451 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2538.

Vanguard Capital Management first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Vanguard Capital Management held 1,897,451 shares of Kyverna Therapeutics worth $16.9M as of Q2 2026.
  • Vanguard Capital Management bought 114,109 Kyverna Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Kyverna Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2538 holding.
  • Vanguard Capital Management first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.